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Summary In this review, the rationale of regional chemotherapy for treatment of hepatic metastases in
advanced colorectal carcinoma is discussed. Pharmacokinetic principles and early clinical experience of hepatic
arterial drug administration are summarised. The regional advantage of fluoropyrimidine compounds in this
setting is well established, and recent evidence suggests that 5-fluorouracil (5-FU) is more efficacious than the
analogue 5-fluoro-2'-deoxyuridine (FUDR). However, while significantly higher clinical response rates can be
achieved with hepatic arterial infusion (HAI) chemotherapy compared with conventional intravenous drug
administration, patient survival benefit is not significantly different. Several novel approaches to overcome the
limitations of HAI therapy are currently being explored. These include concomitant use of biodegradable
microspheres, which both slow tumour blood flow and enhance tumour drug uptake, and use of vasoactive
agents to redistribute arterial blood flow towards tumours. In addition, novel chemotherapeutic agents which
exploit unique biological characteristics of hepatic tumours are entering clinical trial.
The conventional notion of chemotherapy is of a truly
systemic treatment designed to combat widely disseminated
malignant disease. Colorectal carcinoma is relatively un-
responsive to chemotherapy (Mayer, 1992), despite an in-
creasing understanding of drug mechanisms of action at the
molecular level. To date, systemic 5-FU plus folinic acid is
considered the optimum treatment for metastatic colorectal
cancer, yielding response rates of around 25% and median
survival of around 12 months (Piedbois et al., 1992). These
disappointing results reflect, in part, the narrow therapeutic
ratio of 5-FU and the presence of associated severe systemic
side-effects limiting dose escalation. Regional chemotherapy
affords an alternative method of cytotoxic drug administra-
tion which circumvents the constraints of systemic adminis-
tration, while introducing the concept of targeted drug
delivery to metastatic disease localised to specific components
of the body.
Three levels of tumour targeting have been described (Wid-
der et al., 1979): (1) selective drug delivery to the tumour-
bearing organ, (2) drug delivery biased to tumour rather than
to normal tissue within that organ and (3) enhancement of
uptake of cytotoxic drug by malignant cells. In this context,
regional chemotherapy constitutes first-order targeting. Cur-
rently, the value of this method of drug delivery is being
assessed in a number of different malignancies, but experi-
ence is greatest in the treatment of hepatic metastases from
colorectal carcinoma.
Colorectal carcinoma is the second most common malig-
nancy in the UK and the cause of over 19,000 deaths per
year. Epidemiological studies show that the incidence of
colorectal carcinoma is increasing, with approximately 28,000
new cases now being diagnosed annually. Up to 50% of
patients with colorectal carcinoma develop liver metastases,
from which as many as 70% of patients will subsequently die
(Finlay & McArdle, 1986). As a consequence of the portal
venous drainage system, colorectal cancers metastasise early
to the liver, and post-mortem findings indicate that hepatic
metastases may be the only site of disease spread in 20-30%
of patients (Welch & Donaldson, 1979). The presence of
hepatic metastases is a major prognostic indicator, survival
being largely determined by the extent of hepatic disease at
clinical presentation (Kemeny et al., 1989a).
The median survival of patients with multiple metastases is
3-5 months in most series (Fortner et al., 1984). For patients
with isolated liver metastases, surgical resection may be the
best treatment option, with 20-30% 5-year survival rates
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reported in non-randomised trial settings (Wagner et al.,
1984; Hughes et al., 1986). However, such surgery is only
possible in about 10% of patients and palliative
chemotherapy is currently offered to most patients with
extensive or multiple liver metastases. In view of the poor
results obtained with systemic chemotherapy in this context,
the potential to improve both patient response and survival
by directly targeting treatment to the liver would appear,
intellectually, highly attractive.
Pharmacological rationalefor regional chemotherapy
The rationale for regional drug therapy in the management
ofhepatic metastases is the finding that established malignant
lesions (greater than 1 cm diameter) derive most of their
blood supply from the hepatic artery, in contrast to normal
hepatocytes, which have a dual supply via the portal venous
circulation (Stagg et al., 1984). The concept of delivering
chemotherapy to the liver via hepatic arterial infusion dates
as far back as 1959 (Sullivan et al., 1959), and over the
following 20 years the pharmacological principles governing
regional drug delivery were established.
The principal advantage of regional chemotherapy over
conventional systemic therapy is the possibility of achieving
higher drug concentrations at the tumour site while reducing
systemic exposure and hence toxicity (Dedrick et al., 1978).
The major determinant for such a therapeutic advantage is
the ratio of total body clearance to regional exchange rate,
and mathematical formulae for pharmacokinetic models have
been determined (Chen & Gross, 1980; Collins, 1984). The
pharmacokinetic advantage of intra-arterial drug administra-
tion (Rd) can be quantitatively expressed by the following
equation.
CITB
Rd = 1 +
Q (1-E)
where CITB is the total body clearance obtained during in-
travenous infusion, Q is the blood flow through the treated
organ and E is the extraction ratio (the fraction of drug that
is extracted during a single pass through the treated organ).
The ideal drug for hepatic arterial infusion would have a
high total body clearance and a high extraction rate by the
target organ (Table I). In addition, the slower the blood flow
through the target organ, the greater the extraction ratio and
the greater the regional advantage. Thus, hepatic arterial
infusion of the anti-metabolite 5-FU or its analogue, FUDR,
would theoretically maximise drug exposure to the tumour
capillary bed, but result in low systemic levels and minimal
subsequent toxicity to the patient (Ensminger et al.,
1978).
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Table I Pharmacokinetic characteristics of drugs commonly used
for hepatic arterial administration
Estimated increase in hepatic
exposure by HAI over Hepatic extraction
Drug peripheral infusion ratio
FUDR x 100-400 0.95
5-FU x 50-100 0.30-0.40
Doxorubicin x 1-10 0.45-0.50
Mitomycin C x 3-5 0.10-0.20
Clinical experience with hepatic arterial chemotherapy
Since the introduction of intra-arterial infusion of
chemotherapy to the liver by Sullivan and colleagues, early
reports of treating patients with hepatic metastatic colorectal
cancer claimed objective response rates in excess of 50%,
associated with an increase in survival compared with histor-
ical control groups (Huberman, 1983). However, arterial
placement of exteriorised rigid Teflon catheters in these
uncontrolled trials by either radiographic or surgical means
was associated with frequent patient morbidity, related to
catheter displacement (1-75% prevalence), arterial or
catheter thrombosis (1-22% prevalence), gastroduodenal
haemorrhage (0-9% prevalence) and sepsis. The only pro-
spective randomised controlled trial performed at this time
comparing HAI with systemic therapy was reported by the
Central Oncology Group (Grage et al., 1979), in which 61
patients were randomised to receive either 21 days of a
regional infusion with 5-FU or systemic bolus 5-FU. No
significant difference in response rates or survival duration
between the two groups was observed (Table II). However,
the intra-arterial treatment was associated with a greater
incidence of nausea, vomiting and diarrhoea, in addition to
technical complications related to catheter insertion. Subse-
quent improvements in catheter technology and infusion
pump design and surgical placement techniques have both
simplified and facilitated a previously hazardous method of
drug delivery, with consequent reduction in patient morbidity
(Ensminger, 1987; Niederhuber & Grochow, 1989).
The presumed regional advantage of the 5-FU analogue
FUDR, by virtue of its greater hepatic extraction, has been
tested in five randomised trials for advanced colorectal car-
cinoma with liver metastases, comparing 2 weeks' continuous
HAI of FUDR every 4 weeks against systemic therapy
(Table II). These studies all made use of the more recently
developed implantable constant-infusion device, enabling
longer, more tolerable infusions than was previously possible
by means of an external pump. Consequently, it is now
generally accepted that statistically significantly higher re-
sponse rates can be achieved with regional therapy (42-62%)
than systemic therapy (10-21%). However, only a marginal
survival advantage is apparent. The only one of these trials
to claim a statistically significant improvement in survival is
the French Consortium study, but it should be noted that
half the patients in the systemic arm of this trial received no
chemotherapy whatsoever.
It is argued that the lack of ability of these trials to
demonstrate significant survival benefit is in part due to some
of the studies having a cross-over facility between intra-
venous and intra-arterial groups in case of treatment failure.
However, in these and previous non-randomised regional
chemotherapy studies, between 40 and 80% of patients
treated with regional chemotherapy for solitary hepatic
metastases develop extrahepatic recurrence from which most
patients ultimately die (Niederhuber et al., 1984). In addition,
of particular concern is the unacceptably high degree of local
toxicity associated with regional FUDR. Biliary sclerosis
occurred in 50% of patients in the French study and
chemical hepatitis was documented in 42-79% of patients
overall. Other frequent complications included gastric
ulceration and cholecystitis. Significant technical compli-
cations were apparent, including catheter displacement,
catheter thrombosis, hepatic artery thrombosis, pump pocket
haematoma and peritonitis.
The disappointing results of regional chemotherapy dem-
onstrated by these randomised trials has, not surprisingly, led
to considerable controversy concerning the value of this ap-
proach to the treatment of patients with hepatic metastases
(Kemeny, 1992; O'Connell, 1992). However, despite such
misgivings, these trials clearly demonstrate that regionally
administered chemotherapy can modify the progression of
liver metastases and provide a striking change in the natural
history of the disease, in that most patients die from extra-
hepatic metastatic recurrence. In addition, significantly higher
quantities of cytotoxic agent can be administered while
avoiding the usual side-effects associated with systemic
therapy. Thus, in the absence of any new drugs with poten-
tial to treat metastatic colorectal carcinoma, the challenge to
improve upon these trial results by manipulating this novel
drug delivery system continues to stimulate scientists and
clinicians alike.
New perspectives with 5-FU
A significant limitation of HAI chemotherapy is its failure to
prevent recurrence of disease outside of the liver, an event
which ultimately leads to patient death. Two alternative
strategies have been advanced to address this problem, aimed
at achieving high therapeutic drug levels both within the liver
and in the systemic circulation. Firstly, regional and systemic
chemotherapy could be combined. Secondly, high-dose
chemotherapy could be administered with the intention to
cause overspill into the systemic circulation.
A number of phase II trials have combined hepatic arterial
infusion of FUDR with mitomycin C. By virtue of low
hepatic extraction on hepatic arterial administration, the
advantage of therapeutic systemic levels of mitomycin C can
Table II Summary of randomised trials with intrahepatic vs systemic chemotherapy
Trial drugs Hepatic response
No. of rate (%) time (months) Median survival
patients HAI Systemic HAI Systemic HAI Systemic
COG 61 5-FU 5-FU 34 23 10 13
MSKCCa 99 FUDR FUDR 50 20 17 12
NCOGa 115 FUDR FUDR 42 10 17 16
NCI 50 FUDR FUDR 62 17 17 11
NCCTG 55 FUDR 5-FU 54 21 13 11
French Consortium 163 FUDR 5-FU 43 9 15 11
aCross-over design. Abbreviations: COG, Central Oncology Group, (Grage et al., 1979); MSKCC, Memorial Sloan
Kettering Cancer Centre (Kemeny et al., 1987); NCOG, Northern California Oncology Group (Hohn et al., 1989);
NCI, National Cancer Institute (Chang et al., 1987); NCCTG, National Cancer Chemotherapy Group (Martin et al.,
I990).
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be achieved. However, co-administration of these drugs has
been prematurely abandoned because of an unacceptably
high frequency of arterial thrombosis. Safi et al. (1989)
reported the results of a phase III study using implanted
pumps with dual outflow catheters, enabling both hepatic
arterial and intravenous delivery of FUDR. Extrahepatic
recurrence was reduced from 61% in 23 patients treated with
HAI FUDR alone to 33% in 21 others treated with com-
bined hepatic arterial and intravenous FUDR. Disappoin-
tingly, survival for the two groups was the same. However, a
highly significant difference in survival time was evident
between patients who responded to treatment and those
whose liver metastases remained stable or progressed (median
survival time 31 months vs 16 months), thus demonstrating
the potential benefit of regional chemotherapy in certain
patients.
A number of studies have shown that the elimination
kinetics of 5-FU is non-linear, with both systemic clearance
and hepatic extraction of the drug decreasing at very high
dose rates (Wagner et al., 1986). These observations are
consistent with the loss in selective regional advantage
achieved with hepatic arterial infusion of 5-FU administered
at the maximum tolerated dose. What initially appeared to be
a negative feature of regional 5-FU administration has subse-
quently been recognised to be a positive advantage for
achieving both intrahepatic and extrahepatic disease control.
While the solubility and potency of 5-FU is lower than that
of FUDR, necessitating higher volume infusions, an external
pump and surgical or radiological placement of arterial
catheter, regional 5-FU is considerably less toxic than FUDR
and hepatobiliary toxicity is not a feature.
In a series of pharmacokinetically guided studies, it has
been shown that 24 h hepatic arterial infusion of 5-FU con-
fers significant pharmacological advantage relative to in-
travenous infusions or intra-arterial bolus administration
(Goldberg et al., 1988, 1990). Further evidence suggests that
modulation of regional 5-FU administration with folinic acid
might confer significant therapeutic advantage (Anderson et
al., 1991). Unfortunately, regional administration of folinic
acid precipitated hepatic artery occlusion in some patients,
while in previous studies with regional FUDR (Kemeny et
al., 1989b), it had been shown to potentiate the risk of biliary
sclerosis. Therefore, folinic acid is now administered
systemically only.
A recent phase I study was performed with the aim of
generating high intrahepatic 5-FU concentrations while
maintaining adequate therapeutic systemic levels. The recom-
mended dose of hepatic arterial 5-FU as a 24h infusion
when given in combination with a fixed dose of intravenous
folinic acid (400 mgM-2) once per week (Anderson et al.,
1992) was found to be 1.5 gm 2 week-'. At this dosage,
neither myelosuppression nor hepatoxicity was apparent,
while dose escalation to 2.0 g m2 week-' 5-FU was
associated with WHO grade 3/4 diarrhoea and vomiting.
Pharmacokinetic data comparing intrahepatic and intra-
venous 5-FU indicated that the maximum tolerated dose of
5-FU was related to systemic 5-FU exposure, implying that
there was overspill of drug into the circulation (J.H. Ander-
son, personal communication).
Based upon these data, a phase II study was performed.
Thirty patients with histologically proven metastases confined
to the liver received weekly 24 h infusion of 5-FU (1.5 g m-2
week-') via an indwelling hepatic arterial catheter, with
folinic acid (400 mgmi-2) administered intravenously. The
response rate of 27 evaluable patients was 44%, with median
survival 18 months. These data compare favourably with
those of previous HAI phase III trials. Of particular signifi-
cance following the FUDR experience is the minimal toxicity
associated with HAI of 5-FU. The therapeutic potential for
this regional drug combination is to be tested in an MRC-
sponsored phase III clinical trial, randomising pharmaco-
kinetically equivalent intravenous and HAI 5-FU plus folinic
acid regimens. The conclusions from this trial will be a major
determinant of subsequent continued research interest in
HAI chemotherapy in the UK.
Biodegradable microspheres
Biodegradable starch microspheres, approximately 40 jm in
diameter, when injected into the hepatic artery, have been
shown to lodge in the microvasculature and block flow for
15-30 min (Dakhil et al., 1982). Co-administration of micro-
spheres and cytotoxic drug results in the drug being trapped
in a relatively stationary fluid column, allowing greater
exposure time to the surrounding tissues. In an early report,
a bolus injection of mitomycin with 9 x 107 microspheres
resulted in up to 70% reduction in systemic drug exposure
(Gyves et al., 1983) with 4- to 9-fold increase in hepatic
extraction compared with intravenous administration of
mitomycin C (MMC). Such potential therapeutic advantage
could not be reproduced by Goldberg et al. (199la), who
found that arteriovenous shunting in seven patients with
colorectal metastases was minimal (2.2 ± 1.8%) and was not
significantly increased by regional administration of a
therapeutic quantity - 0.5 x 106 - of microspheres (3.0 +
0.8%). Indeed, in a controlled trial of 61 similar patients
(Hunt et al., 1990) randomised to receive either hepatic artery
embolisation, HAI with 5-FU and microspheres or no active
intervention, median survival of treated patients vs controls
(9 months, 13 months and 10 months respectively) was not
significantly different. However, patients with low-volume
hepatic disease appeared to fare better.
An alternative approach has been to encapsulate drugs
within injectable particles. MMC (Kato et al., 1980) has been
incorporated into ethylcellulose microcapsules, but these mic-
rocapsules are not biodegradable and permanently occlude
the vessels in which they lodge. Although resulting tumour
infarction and ensuing hypoxia enhance the therapeutic effect
of prolonged regional drug exposure of MMC, this effect
precludes repeated courses of treatment, while also damaging
normal hepatic parenchyma. Attempts have been made to
microencapsulate MMC using polylactide-glycolide polymers,
and initial formulations have produced a 20-30 jim micro-
capsule with appropriate drug-release characteristics. A phase
I clinical trial has been initiated (Whateley et al., 1992) and it
is conceivable, given the non-overlapping toxicities of MMC
and 5-FU, that the microcapsules serve an additional role in
current strategies of HAI of 5-FU in hepatic metastatic
colorectal carcinoma.
Use ofvasoactive agents to modify tumour bloodflow
The distribution of arterially administered chemotherapy
reflects the pattern of arterial blood flow within the liver. The
disappointing results of regional chemotherapy may be due
to the relatively hypovascular nature of hepatic metastases
(Taylor et al., 1979), limiting homogeneous drug delivery to
the tumour. Indeed the presence of hypovascularised meta-
stases, as defined by radionuclide liver scan with technetium-
99m-labelled microaggregated albumin, is recognised as a
negative prognostic determinant of response in patients
receiving hepatic arterial chemotherapy (Rougier et al.,
1991).
Vasoactive agents have been used in animal models to
modify arterial blood flow, by causing temporary arteriolar
constriction in normal blood vessels (Burton et al., 1985).
Newly formed blood vessels in tumour tissue lack both
smooth muscle and adrenergic innervation (Mattson et al.,
1977) and are therefore less responsive to vasoactive drugs
than those of normal liver tissue. The vasoconstrictor
angiotensin IT has been shown to increase blood flow to
hepatic metastases relative to normal tissue in patients
(Sasaki et at., 1985). A 4 mn infusion of angiotensin II
(lOilgmin-m) via a hepatic artery catheter induced an in-
crease in tumour blood flow by approximately 300% relative
to the normal liver. By the same mechanism, angiotensin II
could potentially influence drug targeting. This was shown by
Goldberg et al. (199lb), who performed scintigraphic studies
of the liver in nine patients with colorectal liver metastases
after (1) intravenous injection of albumin colloid, (2) hepatic
arterial injection of a tracer amount of radiolabelled albuminHEPATIC ARTERIAL CHEMOTHERAPY 375
Table III Pharmacokinetic studies of intravenous (i.v.) and HAI 5-FU with and without albumin microspheres and
angiotensin II in patients with advanced colorectal liver metastases
Treatment No. of 5-FU AUC Clearance ti
regimen patients regimen (mg I min-') (I min -) (min)
5-FU 9 i.v. Ig bolus 1172±365 0.94±0.3 17±5
5-FU 7 i.v. 1 g 2 h infusion 1200 262 1.7 ± 0.2
5-FU 5 i.v. I g 24 h infusion 54 18 18± 7
5-FU 9 HAI 1 g bolus 1312 325 0.81 ±0.2 17 6
AMS+5-FU 9 HAI Ig bolus 1115±481 1.01±0.3 17±6
AII + AMS + 5-FU 9 HAI I g bolus 1403 461 0.78 0.3 7 3
5-FU 7 HAI 1 g 2 h infusion 788 104 2.7 0.4
5-FU 5 HAI I g 24 h infusion 24 18 42 27
Abbreviations: AUC, area under the curve; t1, plasma half-life of 5-FU; AMS, albumin microspheres, 350 mg; All,
angiotensin II, 10 tg min-'.
Values expressed as mean ± standard deviation. All 5-FU concentrations were measured in peripheral venous
plasma.
microspheres and (3) hepatic arterial injection of albumin
microspheres given immediately after a 100 s arterial infusion
of 10 .g of angiotensin II. The median tumour-normal ratio
of radioactivity determined by both scintigraphic planar and
tomographic imaging was 3.4:1 before and 7.3:1 after
angiotensin II administration. In a further study, scintillation
counting of paired tumour and normal liver biopsies taken
from patients following angiotensin II and radiolabelled
microsphere tracer administration showed that the uptake of
microspheres in tumour was 3-fold greater than that in nor-
mal liver (Goldberg et al., 1991c). Tested in phase II clinical
trial (Goldberg et al., 1990), 21 patients receiving an infusion
of angiotensin 11 (10fg min-') followed by bolus HAI of
microspheres and 1 g at 5-FU 4 to 6 weekly tolerated treat-
ment well. Seven patients showed clinical response, while the
median survival of 9 months suggested some significant
therapeutic benefit compared with that of historical con-
trols.
Unfortunately, the effect of angiotensin II is short-lived,
while prolonged infusion causes significant rises in systemic
blood pressure. Alternative vasoactive agents including
vasopressin (Jenkins et al., 1984) and verapamil (Kaelin et
al., 1982) have shown therapeutic potential in animal tumour
models, but their clinical application remains to be explored.
In clinical practice, use of angiotensin II with or without
albumin microspheres has not been shown to significantly
alter the pharmacokinetics of bolus HAI 5-FU (Table III). It
would appear that current optimum regional chemotherapy
with 5-FU involves prolonged infusion, and enhancement of
5-FU cytotoxicity by any chemico-biological agent other
than folinic acid remains to be proven.
Arterial administration ofmacromolecules
Most conventional chemotherapeutic agents are small
molecules of less than 2 kDa in size, with short half-lives as a
consequence of rapid renal excretion. Macromolecules of
50 kDa or more in size have been shown to accumulate
passively within tumours as a result of increased vascular
permeability of tumours and their lack of a lymphatic
drainage system (Maeda et al., 1992). SMANCS (Maeda et
al., 1984) is a 15.5 kDa conjugate of the anti-tumour protein
neocarzinostatin (NCS) and two chains of the synthetic co-
polymer styrene-maleic acid (SMA), which binds to albumin
in plasma, with an effective molecular weight of around
83 kDa (Figure 1). Polymer conjugation of NCS affords a
10-fold increase in half-life and enhanced stability, both in
vitro and in vivo.
The Japanese have accumulated over 10 years of experi-
ence with SMANCS, which has now been administered to
a
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Figure 1 a, Structure of SMA, poly(styrene-co-maleic acid/anhydride) half-butylester. b, Diagrammatic representation of the
reaction with NCS to produce the conjugate SMANCS.376 P.G. DE TAKATS et al.
over 200 patients with primary hepatocellular carcinoma.
HAI of SMANCS administered as a formulation with the
lipid contrast medium Lipiodol is associated with a tumour-
systemic drug concentration ratio of greater than 2,500. In a
pilot phase II study (Konno et al., 1983), 44 patients with
advanced hepatoma received a total of 88 bolus injections of
SMANCS/Lipiodol via the hepatic artery. Treatment resulted
in a decrease in alpha-fetoprotein in 86% of patients and a
reduction in tumour size in 95% of patients. While the
median survival of such patients in Japan treated conven-
tionally with chemotherapy plus or minus surgery is around
6 months, there is now accumulating data which show that
survival of patients 3 years after treatment with, on average,
four courses of HAI SMANCS/Lipiodol ranges between 30
and 90%, depending on the extent of liver involvement and
the presence or absence of cirrhosis (Maeda, 1991).
Furthermore, it would appear that SMANCS has broad-
spectrum activity, being effective against a number of
different solid tumours. Konno et al. (1984) reported their
experience of treating 24 patients with a variety of solid
tumours, 11 ofwhom had colorectal hepatic metastases. HAI
with SMANCS/Lipiodol resulted in tumour response in ten
of these patients, four of whom underwent subsequent resec-
tion of their residual tumour. The median survival ofpatients
with unresectable tumours was 8 months, compared with
around 4 months for untreated patients. Associated toxicity
is remarkably low, comprising low-grade fever and mild
abdominal discomfort only, while biochemical and haemato-
logical changes comprise only a transient rise in liver
enzymes and moderate leucocytosis. It is anticipated that
SMANCS will shortly be entering clinical trial in association
with the Liver Unit, Queen Elizabeth Hospital, Birmingham,
UK.
Patient selection infuture HAI trials
There is now sufficient clinical trial data available on regional
chemotherapy to enable the definition of clinical parameters
which may predict both response to treatment and survival,
in order to select patients most likely to benefit from regional
chemotherapy (Kemeny et al., 1989a; Rougier et al., 1991).
The most important factor affecting survival appears to be
the extent of liver involvement, while the only significant
factor predicting response to hepatic arterial chemotherapy is
perfusion character: hypovascular tumours respond poorly
compared with well-perfused tumours. Methods for detecting
occult hepatic metastases in colorectal cancer which are being
developed include duplex sonography (Leen et al., 1991) and
dynamic hepatic scintigraphy (Hemingway et al., 1992). Ear-
lier detection leading to more rapid referral of patients with
low-volume hepatic metastatic disease should result in im-
proved response to regional chemotherapy and ultimate gain
in patient survival.
Conclusions
Systemic chemotherapy administration in metastatic colorec-
tal carcinoma is limited by the inherent resistance of this
tumour type to conventional cytotoxic drugs and by the steep
dose-response curve of conventional drugs, since dose
escalation is hindered by unacceptable toxicity. Regional
drug delivery to the major site of tumour burden has been
extensively researched in the treatment of colorectal hepatic
metastases. Initial optimism based on sound mathematical
and pharmacokinetic principles has, over the years, been
dampened by the inability to demonstrate theoretical poten-
tial in clinical practice. However, more recent innovative
strategies aimed at exploiting inherent biological and phar-
macological characteristics have revitalised this field of
research, enabling new avenues to be explored.
Clearly, taking into account the high costs incurred in
administering regional chemotherapy, both to the patient and
financially, regional chemotherapy will remain an investiga-
tional procedure until significant therapeutic advantage in
terms of survival benefit can be demonstrated. However, the
desperate predicament of large numbers of patients for whom
there is currently little option for treatment provides a
stimulus to all cancer physicians and surgeons to maintain an
interest in hepatic arterial drug delivery systems and support
randomised trials in this area.
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